DALLAS, June 11, 2025 — Nanoscope Therapeutics Inc., a biotech company pioneering gene-agnostic therapies to restore vision in blind patients suffering from retinal degenerative diseases, today announced its participation in multiple high-profile sessions at the 2025 BIO International Convention, taking place June 16–19 in Boston, Massachusetts. The company’s participation will feature Dr. Samarendra Mohanty, President & Chief Scientific Officer, spotlighting breakthrough innovations in gene therapy for retinal degenerative diseases, while also sharing updates on key milestones achieved on the path to deliver a first-in-class therapy to patients with the highest unmet needs in ophthalmology.

Panel Discussion: Improving and Restoring Vision in Blinding Eye Diseases

• Date & Time: Tuesday, June 17, 2025 | 1:45 – 2:45 p.m. EST
• Location: Boston Convention & Exhibition Center, Room 254B

Dr. Mohanty joins a panel of fellow biotech ophthalmology executives to discuss innovation and investment in the development of cutting-edge therapies for blinding diseases. He will offer insight into how Nanoscope’s positive interactions with regulatory agencies and recent clinical and cost-effectiveness evaluations by ICER, the Institute for Clinical and Economic Review, are shaping the company’s go-to-market strategy.

Concept to Cure – From Bench to Breakthroughs: Developing a New Generation of Restorative Gene Therapies

• Date & Time: Tuesday, June 17, 2025 | 6:30 – 8:00 p.m. EST
• Location: Renaissance Boston Seaport District

At this event, Dr. Mohanty explores Nanoscope’s journey to develop groundbreaking, gene-agnostic therapies designed to restore vision without genetic testing via a one-time, in-office injection— a game-changer in reducing barriers to care. He’ll also discuss how Nanoscope leverages real-world patient data to ensure patient access.

BIO Company Presentation: Gene-Agnostic Therapies for Restoring Vision in Retinal Degenerations

• Date & Time: Wednesday, June 18, 2025 | 9:30 – 9:45 a.m. EST
• Location: Boston Convention & Exhibition Center, Room 154

In this presentation, Dr. Mohanty will share Nanoscope’s exciting past year of milestones with the FDA and ICER as it sets the standard for how gene-agnostic therapies for patients with severe vision loss are evaluated.

Meet with Us at BIO 2025
Nanoscope executive leadership will be available throughout the convention for meetings to discuss partnership opportunities, clinical developments, and the company’s mission to bring back the light of hope to those suffering from retinal degenerative diseases. Send a note to BD@nanostherapeutics.com to schedule a meeting.

About Nanoscope

Nanoscope Therapeutics is developing gene-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial for Retinitis Pigmentosa (RP) (NCT04945772), a rolling FDA BLA submission is planned to commence in June 2025. If approved, MCO-010 has the potential to be the standard of care for RP patients, administered as a one-time, in-office injection without the need for genetic testing. The company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt Disease (SD) (NCT05417126) and plans to initiate a Phase 3 registrational trial in 2025. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD. Preclinical programs include Leber Congenital Amaurosis (LCA), in IND-enabling studies, as well as an IND-ready asset for geographic atrophy (GA).

Investor Contact:
Nanoscope Therapeutics
(817) 857-1186
PR@nanostherapeutics.com

DALLAS, May 12, 2025 /PRNewswire/ — Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced multiple presentations at the 28^th annual meeting of the American Society of Gene and Cell Therapy (ASGCT 2025), to be held at the Ernest N. Morial Convention Center in New Orleans, May 13-17^th, 2025.  Nanoscope’s presentations will be centered around the company’s MCO-010 optogenetic therapy for retinal degenerative diseases. MCO-010 is the most advanced program in the MCO (multi-characteristic opsin) platform and the first and only mutation-agnostic therapy shown to restore vision in advanced RP patients via a one-time, standard intravitreal injection.

“We are excited to present the safety and efficacy results of our MCO therapy for multiple retinal diseases, including Stargardt macular degeneration in clinical trials, and geographic atrophy in non-human primate models,” said Dr. Samarendra Mohanty, co-founder and President of Nanoscope. “In addition to presenting robust assays for ensuring the potency of MCO-010, we look forward to sharing details about the positive therapeutic benefits seen in Stargardt patients, which were similar to the durable vision gains in patients with retinitis pigmentosa (RP). It is an exciting time at Nanoscope as we prepare MCO-010 for commercialization, including BLA submission.”

Following are the details for the meeting presentations:

Full Agenda

Podium presentations:

• Tuesday, May 13^th,  2:15 pm – 2:30 pm; Room 265-268 – Dr. Samarendra Mohanty presenting – “Safety and efficacy of multi-characteristic opsin gene therapy in improving vision in NHP model of geographic atrophy“

• Tuesday, May 13^th, 2:30 pm – 2:45 pm; Room 288-290 – Dr. Saurav Mohanty presenting – “Safety, Tolerability, Biodistribution, Transgene Expression and Effectiveness of Image-Guided Laser-based Non-Viral Targeted Delivery of Multi-Characteristic Opsin in Retinae of African Green Monkeys“

• Wednesday, May 14^th, 4:00 pm – 4:15 pm; Room 265-268– Dr. Subrata Batabyal presenting – “Development of Orthogonal Potency Assays for Multi-Characteristic Opsin Gene Therapy: Gene Expression and Light-Stimulated Activity“

Poster presentations:

• Tuesday, May 13^th,  6:00 pm – 7:30 pm; Poster Hall – Dr. Vinit Mahajan presenting – “Human Retinal Cell Delivery of a Bioengineered, Synthetic Protein Sensitive to Multiple Wavelengths of Light in Patients with Stargardt Disease”, Poster No. 584

• Wednesday, May 14^th, 5:30 pm – 7:00 pm; Poster Hall – Dr. Amir Singh presenting – “Forced Degradation Studies of Multi-Characteristic Opsin Gene Therapy Drug Product”, Poster No. 1380

• Thursday, May 15^th, 5:30 pm – 7:00 pm; Poster Hall – Dr. Ananta Ayyagari presenting – “Accelerated Regulatory Approvals in Cell and Gene Therapy”, Poster No. 1856

Nanoscope team members will also be available for meetings during the ASGCT conference.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing mutation-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases for which no treatment currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial, also in 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.

Investor Contact:
Nanoscope Therapeutics
(817) 857-1186
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

DALLAS, May 1, 2025 — Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced that Dr. Subrata Batabyal, Director of Nonclinical Development, has received 2025 Carl Camras Translational Research Award from the ARVO Foundation for his pioneering work in optogenetic vision restoration.

The award, which comes with a $12,000 prize, recognizes early-career investigators engaged in translational research. Dr. Batabyal significantly contributed to the translation of multi-characteristic opsin (MCO-010), an innovative gene therapy that uses light-sensitive proteins to restore vision in patients with inherited retinal diseases. The therapy has successfully progressed from laboratory studies to clinical trials, demonstrating promising results in treating patients with retinitis pigmentosa and other inherited retinal disorders. Dr. Batabyal will receive the award during The Association for Research and Vision in Ophthalmology (ARVO) 2025 annual meeting, to be held in Salt Lake City from May 4-8.

The ARVO Foundation Awards Reception details are as follows:

Date: Sunday, May 4, 2025
Time: 11:45 am – 1:00 pm MT
Location: Calvin L. Rampton Salt Palace Convention Center, Room 155EF

“Dr. Batabyal continues to lead groundbreaking research initiatives in vision restoration at Nanoscope,” said Dr. Samarendra Mohanty, Co-Founder and President of Nanoscope. “He is representative of the outstanding team we have assembled, which is developing next-generation vision restoration treatments that could benefit potentially millions of patients worldwide who currently have limited treatment options.”

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate in 2025 a BLA submission for MCO-010 to treat RP. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial in 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready, non-viral, laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

DALLAS, April 25, 2025  — Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced participation at both the Eyecelerator and The Association for Research and Vision in Ophthalmology (ARVO) 2025 annual meetings. Nanoscope’s presentations will be centered around 126-week outcomes following treatment with its MCO-010 optogenetic therapy for retinitis pigmentosa (RP), the first and only therapy shown to restore vision in advanced RP patients via a one-time, standard intravitreal injection.

“We are excited to have such a substantial presence at both the Eyecelerator and ARVO annual meetings and look forward to sharing more about the positive therapeutic benefits seen in RP patients treated with our multi-characteristic opsin, or MCO, therapy,” said Dr. Samarendra Mohanty, co-founder and President of Nanoscope. “Multi-year benefit is meaningful for patients looking for a one-time, durable treatment option for their irreversible, progressive vision loss due to RP, and it underscores the potential of MCO-010 to redefine the standard of care. It is an exciting time at Nanoscope as we prepare MCO-010 for commercialization, including BLA submission.”

Details of the presentations are as follows:

Eyecelerator 
Friday, May 2^nd, 2025
Grand Hyatt Deer Valley, Park City, UT

Nanoscope participation:

• 12:30 – 1:30pm MDT – Panel – I Shall be Released: Novel Drug Delivery Approaches for Glaucoma and Retina – Dr. Sam Barone, Chief Medical Officer
  
  
• 1:59 – 2:04pm MDT; Strawberry Ballroom – Presenting Company Showcases: Retina: Gene Therapy and Novel Mechanisms of Action – Dr. Jared Stephens, Vice President, Strategy and Business Development
  
  
• 3:30 – 4:15pm MDT – Panel – No Direction Home: Guidance for Navigating Increasingly Complex Regulatory Pathways – Dr. Sam Barone

ARVO, The Association for Research in Vision and Ophthalmology
Sunday, May 4^th to Thursday, May 8^th, 2025
Salt Palace Convention Center, Salt Lake City, UT

Nanoscope presentations:

• Sunday, May 4^th, 1:30 – 1:45pm MDT; Ballroom G – Ms. Lucero Garcia presenting – “Multi-characteristic opsin gene therapy attenuates retinal degeneration and restores vision in NHP model of geographic atrophy”
  
  
• Tuesday, May 6^th, 9:15 – 9:30am MDT; Ballroom B – Dr. SriniVas Sadda presenting – “126-Week Visual Acuity Outcomes Following Mutation-Agnostic Optogenetic Therapy, MCO-010, for Retinitis Pigmentosa (RP)”
  
  
• Thursday, May 8^th, 2:45 – 3:00pm MDT; Ballroom F – Dr. Naj Sharif presenting – “Safety and Efficacy of an Image-Guided Laser-based Non-Viral Targeted Delivery of Multi-Characteristic Opsin Plasmids in African Green Monkey Retinae”

Nanoscope team members will be available at Booth 1337 for the duration of the ARVO conference.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing mutation-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases for which no treatment currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in H1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial, also in 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

DALLAS, March 27, 2025  — Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in individuals who are blind or losing vision due to various retinal degenerative diseases, today announced that Ashish Patel, PhD, has joined the company as Senior Vice President, Sales and Marketing. Dr. Patel is a recognized leader with proven results across brand, sales and research and development management for some of the world’s most recognized startup biotech and pharmaceutical organizations.

“With his unique blend of scientific and commercial expertise, particularly in the treatment of retinal diseases, Dr. Patel is well-equipped to drive Nanoscope’s sales and marketing strategy as we move towards commercialization of our optogenetic therapies,” said Sulagna Bhattacharya, co-founder and CEO of Nanoscope Therapeutics.

Dr. Patel has extensive experience in aligning scientific and commercial insights to inform strategic and business decisions with a focus on patients.  Most recently, he served as Vice President of Sales for Iveric Bio (now Astellas), launching IZERVAY™, a treatment for geographic atrophy. Prior to Iveric, Dr. Patel spearheaded marketing and launch efforts for Novartis’ BEOVU®, used to treat chronic eye conditions, including wet age-related macular degeneration (AMD). His tenure at Bayer spanned over a decade, during which he held multiple brand, sales and research management roles. Notably, he served as the global launch lead for the fastest-growing indication within Bayer’s blockbuster EYLEA® retina business. He began his career as a senior research and development scientist with Novartis.

Dr. Patel received a Master of Business Administration from New York University Stern School of Business and holds a PhD in physiology and biophysics from Stony Brook University. Dr. Patel was a graduate fellow in molecular biology at the Massachusetts Institute of Technology and earned his Bachelor of Science in biophysics from the University of Southern California.

“Nanoscope is at the precipice of being the first to deliver life changing, mutation-independent therapies to patients with the highest unmet needs in retina,” said Dr. Patel. “I’m excited to join the accomplished team at Nanoscope, and I look forward to helping lead our commercialization and launch preparations as we progress in our mission to help the millions of patients worldwide impaired by retinal degenerative diseases for which no treatment currently exists.”

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing mutation-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases for which no treatment currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in H1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial, also in the first half of 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.

Investor Contact:
Argot Partners
212-600-1902 
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

DALLAS, March 24, 2025 — Researchers with Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, have announced the publication of a paper, “A synthetic opsin restores vision in patients with severe retinal degeneration,” in Molecular Therapy, the flagship journal of the American Society of Gene & Cell Therapy.  The publication of the paper marks a major breakthrough in mutation-independent optogenetic monotherapy for patients suffering from inherited retinal diseases.

“We are excited by the therapeutic benefits seen in retinitis pigmentosa patients with progressive and permanent loss of photoreceptors and without any treatment option,” said Dr. Santosh Mahapatra, the principal investigator for the study, and Chief Medical Officer of JPM Rotary Eye Hospital (Odisha) in India. “We look forward to further advancing this technology to help those with severe vision loss due to retinal degenerative diseases.”

Inherited retinal degenerative diseases (IRDs) are the leading cause of blindness in working-age adults worldwide, and in advanced stages, cell loss makes gene editing or replacement ineffective. Optogenetics offers a therapeutic opportunity to restore vision by photosensitizing remaining retinal neurons. However, current opsins are kinetically slow, partially activated in ambient light, unresponsive to different light colors, and target low-resolution retinal cell circuits. To overcome these limitations, the Nanoscope team engineered a synthopsin made of three selectively mutated non-mammalian proteins to achieve a broadband Multi-Characteristic Opsin (MCO).

“This paper highlights the outstanding work of the Nanoscope team in developing effective optogenetic therapies for patients with some of the highest unmet needs,” said Dr. Samarendra Mohanty, the lead author of the paper and President of Nanoscope. “The positive results of our Phase 1/2a trial outlined in this journal article, along with the randomized controlled trial data in RP, represent a major step forward in treating inherited retinal diseases.”

The engineered synthopsin was packaged into an optimized AAV2 gene therapy vector that targets human retinal bipolar cells. In an investigator-initiated, open-label study, four blind retinitis pigmentosa patients with ABCA4 variants received a single intravitreal gene therapy injection. Noninvasive imaging confirmed retinal gene expression via a fluorescent reporter protein. Patients showed improvement in visual acuity, shape discrimination, and mobility through the 52-week study period. There were no significant safety issues despite what is likely one of the most synthetic, non-mammalian proteins ever expressed in a human. This is the first report of a gene monotherapy that can restore vision in blind patients in a mutation-independent manner utilizing an optogenetics technology platform.

“Our study represents a pivotal milestone in the treatment of inherited retinal degenerations, demonstrating that optogenetics can successfully restore vision in blind patients, regardless of their genetic mutation,” said Dr. Vinit B. Mahajan, co-corresponding author and Professor and Vice Chair for Research, Department of Ophthalmology at Stanford University. “The ability to restore vision with a single intravitreal injection marks a significant step toward developing a universal treatment for retinal degenerative diseases.”

Click here to access the full paper and graphical representation of the clinical study.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing mutation-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases for which no treatment currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in H1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial, also in the first half of 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

DALLAS, March 20, 2025  — Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced that Ademola Daramola, D.Sc., has joined the company as Vice President, Quality and Compliance. Dr. Daramola has more than two decades of experience developing processes and managing workflows for a wide range of quality assurance, compliance and operational excellence in human drugs, vaccines and medical devices.

“Ademola is an accomplished leader in quality assurance and compliance across different functions, with deep experience in the pharmaceutical industry, including with the FDA,” said Sulagna Bhattacharya, co-founder and CEO of Nanoscope. “His expertise will be invaluable as we advance toward commercialization of our optogenetic therapies.”

Dr. Daramola has an extensive background in leading cross-functional teams, developing processes, and managing workflows for a wide range of quality assurance and compliance programs in the pharmaceutical and medical device industries. Most recently, he served as GMP Compliance Leader for the Bill & Melinda Gates Medical Research Institute, where he was responsible for ensuring that Gates MRI biologics, vaccines, and small molecules, manufactured at third-party sites, complied with requisite quality and safety regulations. Prior to that, he was Vice President and Global Head of Quality and Compliance for CIPLA. Dr. Daramola spent nearly eight years with the FDA as an International Relations Specialist and a Consumer Safety Officer for Drug and Medical Devices. He began his career as a chemist with Teva Pharmaceuticals. Dr. Daramola earned his doctorate and master’s degrees in Global Health from Nova Southeastern University. He has a Bachelor of Technology from Barry University, as well as a Bachelor of Science from Ondo State University in Nigeria.

“Nanoscope is at an important inflection point both in its growth as a company and with its lead candidate, MCO-010,” said Dr. Daramola. “I’m excited to work with this dynamic and talented team and I look forward to ensuring the highest standards of quality and compliance as we bring these life-changing therapies to patients.”

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing mutation-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases for which no treatment currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in H1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial, also in the first half of 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

DALLAS, March 13, 2025 — Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in individuals who are blind or losing vision due to various retinal degenerative diseases, today announced that Sulagna Bhattacharya, Chief Executive Officer and Co-Founder of Nanoscope Therapeutics, will present at the H.C. Wainwright 3^rd Annual BioConnect Showcase, taking place March 16-18, 2025, on Kiawah Island, SC. Details for the presentation are as follows:

Ms. Bhattacharya will provide an overview of Nanoscope and give an update on the Company’s clinical and corporate activities on Monday, March 17, at 9:40 AM Eastern Time in the Grand Oaks ballroom.

The executive team will be available to meet with investors during the event.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in H1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial, also in the first half of 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

DALLAS, Feb. 6, 2025  — Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced that Sulagna Bhattacharya, Chief Executive Officer and Co-Founder of Nanoscope Therapeutics, will present at the BIO CEO & Investor Conference, taking place February 10-11, 2025, in New York, NY. Details for the presentation are as follows:

Ms. Bhattacharya will provide an update on Nanoscope’s clinical and corporate activities on Monday, February 10, at 4:30 PM Eastern Time in the Plymouth Room. Nanoscope leadership will be available for meetings during the conference. Attendees interested in scheduling a meeting may do so through the BIO One-on-One Partnering system: https://www.bio.org/events/bio-ceo-investor-digital-conference/partnering.

“With our upcoming BLA submission for MCO-010, Nanoscope is on the cusp of providing meaningful sight restoration for patients suffering from retinitis pigmentosa,” said Ms. Bhattacharya. “I appreciate this opportunity to highlight for attendees the benefits and applications of MCO-010 therapy as well as discuss our other clinical programs in development for indications with significant unmet need. I’m looking forward to another productive event.”

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in Q1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial in Q1 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

DALLAS, Feb. 4, 2025  — Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced presentations at two upcoming medical meetings. Details of the presentations are as follows:

Bascom Palmer Eye Institute’s 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting

Title: Longitudinal Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients with Severe Vision Loss Due to Retinitis Pigmentosa: 126-Week Results from a Long-Term Follow-Up Study (REMAIN)
Session Title: Inherited Retinal Degenerations
Session Date: Saturday, February 8, 2025
Session Time: 6:25 p.m. ET
Presenter: Allen Ho, MD, FACS, FASRS, Director of Retina Research and Co-Director of the Retina Service at Wills Eye Hospital, and Chief Medical Advisor of Nanoscope

Dr. Ho will participate in a panel discussion on inherited retinal dystrophies (IRDs), for several of which, Nanoscope is developing restorative treatments. As part of this, Dr. Ho will discuss 126-week data from Nanoscope’s REMAIN long-term follow-up study of advanced retinitis pigmentosa patients dosed in the RESTORE randomized controlled trial.

The Macula Society 48th Annual Meeting

Title: Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients With Severe Vision Loss Due to Retinitis Pigmentosa: 126-Week Topline Results from the REMAIN Follow-Up Study (REMAIN)
Session Title: Inherited Retinal Dystrophy I
Session Date: Thursday, February 13, 2025
Session Time: 7:05 a.m. ET
Presenter: Victor Gonzalez, MD, Gulf Coast Eye Institute and REMAIN trial investigator

Dr. Gonzalez will present and discuss long-term follow-up efficacy and safety data of Nanoscope’s MCO-010 optogenetic therapy for vision restoration in patients with severe vision loss due to retinitis pigmentosa.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in Q1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial in Q1 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

DALLAS, Jan. 20, 2025 — Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced several presentations by company leadership at the 21^st  Annual Advanced Therapies Week Conference, taking place from January 20-23, 2025 at the Kay Bailey Hutchinson Convention Center in Dallas, Texas. Details for the presentations are as follows:

Title: Navigating the Challenges of Gene Therapies for Rare Diseases
Session Title: Gene Therapy for Rare Disease
Session Date: January 21, 2025
Session Time: 12:15 p.m. C.T.
Presenter: Samarendra Mohanty, PhD, President & Chief Scientific Officer

Dr. Mohanty will discuss key challenges to modern gene therapy programs for rare disease indications. These will include the general lack of suitable animal models, established clinical endpoints, and validated analytics and manufacturing processes, which in most cases need to be implemented by the gene therapy developer.

Title: Partnering for Commercialization, a CMC Prospective
Session Title: Partnering for Gene Therapy Success
Session Date: January 21, 2025
Session Time: 4:30 p.m. C.T.
Presenter: Raymond Kaczmarek, Chief Technical and Manufacturing Officer

During his presentation, Mr. Kaczmarek will highlight several key internal and external considerations paramount to ensuring a successful CDMO relationship and overall manufacturing program for gene therapy programs.

Session Title: International Convergence and Regulatory Alignment for CGT
Session Date: January 22, 2025
Session Time: 11:00 a.m. C.T.
Chair: Khandan Baradaran, PhD, SVP Regulatory and Quality

Dr. Baradaran will host a fireside chat with Dr. Nicole Verdun, Super Office Director of the Office of Therapeutic Products, CBER, discussing how gene and cell therapy developers can forge productive interactions with regulators to ensure an efficient path toward approval.

Title: Optical Approaches to Non-Viral Redosable Gene Therapies
Session Title: Are Redosable Gene Therapies on the Horizon?
Session Date: January 22, 2025
Session Time: 11:00 a.m. C.T.
Presenter: Subrata Batabyal, PhD, Director, Non-Clinical Development

During his presentation, Dr. Batabyal will discuss the dosing limitations of AAV gene therapies, and how Nanoscope’s non-viral, optical dosing technologies can overcome this limitation by eliminating concerns related to immunogenicity.

Title: First-Line Gene Therapies for Inherited Blindness
Session Title: Innovation Series Company Presentations
Session Date: January 22, 2025
Session Time: 4:00 p.m. C.T.
Presenter: Sulagna Bhattacharya, CEO

During her talk, Ms. Bhattacharya will provide a corporate update on Nanoscope’s recent and upcoming progress across pipeline programs.  She will specifically cover Nanoscope’s lead asset MCO-010, which is slated for BLA submission, as well as the advancement of Nanoscope’s Stargardt program to a registrational Phase 3 trial.

Title: Ensuring Flexibility and Scalability in AAV Gene Therapy Manufacturing
Session Title: Bioprocess Workflows & Analytics for Flexibility and Scalability
Session Date: January 22, 2025
Session Time: 5:00 p.m. C.T.
Presenter: Victor Adeniyi, Senior Director, CMC

During his presentation, Adeniyi will provide an overview of the landscape of analytical and scalability challenges in gene therapy, and discuss the value of designing and incorporating flexibility to address these challenges over time.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in Q1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial in Q1 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

DALLAS, Jan. 9, 2025  — Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced that Chief Executive Officer, Sulagna Bhattacharya, will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 4:00 p.m. PT, in San Francisco.

Ms. Bhattacharya’s presentation will highlight Nanoscope’s progress towards a near-term Biologics License Application (BLA) submission and the subsequent path to the potential launch of its Multi-Characteristic Opsin (MCO-010) product, first-to-market restorative treatment for patients with vision loss from Retinitis Pigmentosa (RP), if approved. She will also discuss the advancement of the Company’s Adeno-associated virus (AAV) pipeline program for Stargardt macular degeneration to a planned single registrational Phase 3 trial, and the progression of a non-viral platform program for geographic atrophy (GA) to a first-in-human trial.

Management will be available for in-person meetings during the conference. To schedule a meeting, please contact nanoscope@argotpartners.com.

About Nanoscope Therapeutics Inc.

Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in Q1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial in Q1 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an IND-ready AAV asset for Leber Congenital Amaurosis.

Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com